PCG
YMAB

Private Capital Group’s Y-mAbs Therapeutics YMAB Stock Holding History

Private Capital Group’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-45
Closed -$2K – 2126
2020
Q2 		$2K Buy
+45
New +$1.7K ﹤0.01% 1743

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Private Capital Group's YMAB Position: Q3 2020 in Review

Private Capital Group sold out of Y-mAbs Therapeutics (YMAB) in Q3 2020, closing a stake of 45 shares — an estimated $2K sold.

Private Capital Group first reported a position in YMAB in Q2 2020 and held it in 1 quarter. The position peaked at $2K in Q2 2020. 106 funds tracked by Wall St. Rank hold YMAB as of Q3 2020.

  • Private Capital Group reported no remaining Y-mAbs Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Private Capital Group sold 45 Y-mAbs Therapeutics shares in Q3 2020, an estimated $2K.
  • Private Capital Group first reported a position in Y-mAbs Therapeutics in Q2 2020 and held it in 1 quarter.
  • Private Capital Group's Y-mAbs Therapeutics position peaked at $2K in Q2 2020.
  • 106 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2020.

Based on Private Capital Group's 13F filing for Q3 2020, filed 12 Nov 2020.